INFORMATION DISCLOSURE CITATION 3-00000 Atty. Docket No. Serial No. 09/809,329 Marie-Christine BISSERY March 16, 2001 Group: 1614

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
MCH	EP 0 056 692 B1	07/28/82	EPO			
	EP 0 088 642 A2	09/14/83	ЕРО			
	EP 0 296 612 B1	12/28/88	EPO			
	EP 0 321 122 B1	06/21/89	EPO			_
	EP 0 325 247 B1	07/26/89	EPO			
	EP 0 540 099 B1	05/05/93	EPO			
	EP 0 737 686 B1	10/16/96	ЕРО			
	WO 96/37496	11/28/96	PCT			
	WO 96/38146	12/05/96	PCT			
MCH	WO 96/38449	12/05/96	PCT			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
M·c·H	T.H. Corbett et al., "Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas," <i>Cancer</i> , 40(5):2660-2680 (1977).						
	T.H. Corbett et al., "Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents," Cancer Treatment Reports, 66(5):1187-1200 (May 1982).						
	David L. Emerson et al., "In vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues," Cancer Research, 55:603-609 (February 1995).						
	Isabelle Madelaine et al., "Sequential Modifications of Topoisomerase I Activity in a Camptothecin-Resistant Cell Line Established by Progressive Adaptation," <i>Biochemical Pharmacology</i> , 45 (2):339-348 (1993).						
M·c·H	T. Saotome et al., "Combination Chemotherapy with Irinotecan and Adriamycin for Refractory or Relapsed Malignant Lymphoma (ML): A Pilot Study," Abstract 540P, Ann. Oncol., 7(Suppl. 5): 113 (1996).						

Examiner \(\)	lichae	-C. Henr.	Date Considere	d 8	/8	/o ¬	<u></u>	
*Examiner:			hether or not citation is in confo d not considered. Include copy					
Form PTO 1449	9		Patent and	Tradema	rk Off	ice - L	J.S. Department of	f Commerce

Applicant

Filing Date

INFORMATION DISCLOSURE CITATION

OMB №	0651	l-00 <u>1.</u> 1
H CE	UL	ñ

Atty. Docket No.	03806.0493-00000	Serial No.	09/809,329	IITEI	ಲ		Ī
Applicant	Marie-Christine BISSERY			16(1 2		
Filing Date	March 16, 2001	Group:	1614	0/2	pot	m	_

		FOREIGN PATE	NT DOCUMENT	S		_ -
OIPE SCIES	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
JUL 2 7 2001 월						
FIRADEMINE.						
& TRADE						
				ļ	_	
				<u> </u>		

M-C++	Frank M. Schabel, Jr. et al., "Chapter 1: Testing Therapeutic Hypotheses in Mice and Man: Observations on the Therapeutic Activity Against Advanced Solid Tumors of Mice Treated with Anticancer Drugs That Have Demonstrated or Potential Clinical Utility for Treatment of Advanced Solid Tumors of Man," Methods in Cancer Research - Cancer Drug Development (Part B), Vol. XVII, pp. 3-51 (1979).
m-c++	P. Vrignaud et al., "In vivo Chemosensitivity of a P388 Murine Leukemia Resistant to Camptothecin," Abstract 2160, Proc. Amer. Soc. Cancer Res., 35:363 (March 1994).
	·

Examiner M	chael	-C	Henry	1	Date Considered	81	18	102		
*Examiner:		not in c	,		itation is in conforn ed. Include copy of			•		-
Form PTO 1449					Patent and Tr	ademark	Offic	e - U.S.	Department of	Commerce

٠ ٠ ٠	SEP 1 0 2000 SINFORMATION	ON DISCLOSURI	E CITATION	OMB No. 7551,001 IT
atty. Docket No.	3806.0493	Serial No.	09/809,329	H 3
pplicant	Marie-Christine BISSERY			001 000/
iling Date	March 16, 2001	Group:	1614	

	U.S. PATENT DOCUMENTS					
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
M·C·H	4,473,692	09/25/84	Miyasaka et al.			
M·(·H	4,545,880	10/08/85	Miyasaka et al.			
M-C.H	6,191,119 B1	02/20/01	Rubinfeld			

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
M·C·H	EP 0 074256 B1	03/16/83	EPO			
M·c·H	WO 90/03169	04/05/90	PCT			
MCH	WO 97/00876	01/09/97	PCT			No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner M	ichael -	C. Henri	1	Date Considered	8	18	02	
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449				Patent and Tra	demarl	c Offic	ce - U.S. Department of Commerce	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

0 5001 Atty. Docket 00000 09/809,329 Serial No. e-Christine BISSERY Applicant Filing Date March 16, 2001 1614 Group

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
M·C·H	JP 57-116015	07/19/82	Japan			
1	JP 57-116074	07/19/82	Japan			
	JP 59-5188	01/12/84	Japan			
	JP 59-51289	03/24/84	Japan			
	ЈР 60-19790	01/31/85	Japan			
	JP 1-246287	10/02/89	Japan	-		
MCIT	JP 1-249777	10/05/89	Japan			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

M-CH	Abstract: Japio No. 00965715 for JP 57-116015.
	Abstract: Japio No. 00965774 for JP 57-116074.
	Abstract: Japio No. 01293588 for JP 59-5188.
	Abstract: Japio No. 01541290 for JP 60-19790.
	Abstract: Japio No. 02948687 for JP 1-246287.
	Abstract: Japio No. 02952177 for JP 1-249777.
	Abstract: Derwent No. 01984-110813/198418 for JP 59-51289.
	Tomio Furuta and Teruo Yokokura, "Combination Therapy of CPT-11, a Camptothecin Derivative, with Various Antitumor Drugs Against L1210 Leukemia," <i>Japanese Journal of Cancer and Chemotherapy</i> , 18 (3):393-402 (March 1991); English Abstract p. 402.
	M. Ise, C. Sakai, H. Tsujimura, K. Kumagai, T. Takenouchi and T. Takagi, "Sucessful Treatment with CPT-11 and Adriamycin for Hemophagocytic Syndrome Associated with Intravascular Lymphomatosis," <i>Jpn J. Clin. Hematology</i> , 39(11):1131-1136; English Abstract p. 1136.
M·C·H	C. Sakai, T. Saotome, A. Takeshita, C. Nakaseko, K. Kumagai, and T. Takagi, "Irinotecan + Adriamycin QOL," <i>Jpn. J. Cancer Chemotherapy</i> 26 (5):709-714 (1999); Chemical Abstract 115:21789.

Examiner Date Considered 18

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation *Examiner:

if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 Patent and Trademark Office - U.S. Department of Commerce